Journal of Cardiovascular Pharmacology and Therapeutics 2010-12-01

Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits.

Donatella Mutolo, Fulvia Bongianni, Stefano Evangelista, Elenia Cinelli, Tito Pantaleo

Index: J. Cardiovasc. Pharmacol. Ther. 15(4) , 384-92, (2010)

Full Text: HTML

Abstract

Cough is the most common symptom reported by patients in a primary care setting and is one of the most frequent secondary effects recorded during treatment with angiotensin-converting enzyme (ACE) inhibitors. The aim of the current study was to analyze potential differences in cough induction between 2 structurally different ACE inhibitors, namely zofenopril, which has a sulphydryl moiety, and ramipril, which has a carboxyl moiety. The cough reflex was induced by chemical (citric acid) and/or mechanical stimulation of the tracheobronchial tree in awake and anesthetized rabbits. Intravenous injection of the active compounds of the 2 ACE inhibitors, zofenoprilat (288 nmol/kg) and ramiprilat (129 nmol/kg), caused similar hypotensive effects in anesthetized rabbits. None of the studied cough-related variables changed in response to ACE inhibitor administration, with the exception of the number of coughs. Ramiprilat, but not zofenoprilat, increased the cough response induced by both mechanical and chemical stimulation (1 mol/L citric acid aerosol) of the tracheobronchial tree. In awake animals, zofenoprilat- or vehicle-treated rabbits did not show any significant changes in the number of coughs induced by 1 mol/L citric acid aerosol compared to their respective basal values (from 15.2 ± 2.3 to 13.1 ± 1.3 and from 16.1 ± 4.9 to 15.8 ± 4.3, respectively). Conversely, ramiprilat resulted in a significant increase in the number of coughs (from 21.1 ± 2.6 to 34.9 ± 3.5; P < .01). These findings confirm that there are differences in the cough potentiation effect induced by different ACE inhibitors. The low rate of cough seen with zofenoprilat may be related to its ability to induce a lower accumulation of bradykinin and prostaglandins at the lung level.


Related Compounds

Related Articles:

Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions.

2009-01-01

[Cardiovasc. Ther. 27(4) , 275-88, (2009)]

Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of zofenopril and its active metabolite zofenoprilat in human plasma.

2011-06-01

[J. Pharm. Biomed. Anal. 55(3) , 527-32, (2011)]

Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS.

2010-12-01

[J. Renin Angiotensin Aldosterone Syst. 11(4) , 243-7, (2010)]

Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2.

2010-12-01

[Naunyn Schmiedebergs Arch. Pharmacol. 382(5-6) , 455-61, (2010)]

Effects of zofenopril on cardiac sarcoplasmic reticulum calcium handling.

2009-11-01

[J. Cardiovasc. Pharmacol. 54(5) , 456-63, (2009)]

More Articles...